1494P Regomune - a phase II study of regorafenib + avelumab in solid tumors: Results of the soft tissue sarcoma (STS) cohort

Cousin, Sophie; Bellera, C.; Guegan, J-P.; Valentin, T.; Bahleda, Rastilav; Metges, J-P.; Cassier, P.; Cantarel, Coralie; Ceruso, Mariella Spalato; Kind, Michèle; Soubeyran, Isabelle; Palussière, Jean; Bessede, A.; Italiano, A.

doi:10.1016/j.annonc.2022.07.1597

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of avelumab plus regorafenib has been tried by a phase II basket trial in advanced solid tumors (REGOMUNE), with an STS cohort including 49 patients (22 LMS, 9 synovial sarcomas, 4 liposarcomas, 4 UPS and 10 other subtypes) [ 105 ]. The results were similar to other combinations of ICI + TKIs, with 4 PR among 43 evaluable patients and a DCR of 48.8%.…”

Section: Immunotherapy For Sarcoma: Clinical Resultsmentioning

confidence: 99%

Current Landscape of Immunotherapy for Advanced Sarcoma

Albarrán

Villamayor

Pozas

et al. 2023

Cancers

View full text Add to dashboard Cite

There is substantial heterogeneity between different subtypes of sarcoma regarding their biological behavior and microenvironment, which impacts their responsiveness to immunotherapy. Alveolar soft-part sarcoma, synovial sarcoma and undifferentiated pleomorphic sarcoma show higher immunogenicity and better responses to checkpoint inhibitors. Combination strategies adding immunotherapy to chemotherapy and/or tyrosine–kinase inhibitors globally seem superior to single-agent schemes. Therapeutic vaccines and different forms of adoptive cell therapy, mainly engineered TCRs, CAR-T cells and TIL therapy, are emerging as new forms of immunotherapy for advanced solid tumors. Tumor lymphocytic infiltration and other prognostic and predictive biomarkers are under research.

show abstract

Section: Immunotherapy For Sarcoma: Clinical Resultsmentioning

confidence: 99%

Current Landscape of Immunotherapy for Advanced Sarcoma

Albarrán

Villamayor

Pozas

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

Role of Immunotherapy in Sarcomas

Dalal,

Shan,

Thaw Dar

et al. 2024

IJMS

View full text Add to dashboard Cite

Sarcomas are a group of malignancies of mesenchymal origin with a plethora of subtypes. Given the sheer heterogeneity of various subtypes and the rarity of the disease, the management of sarcomas has been challenging, with poor patient outcomes. Surgery, radiation therapy and chemotherapy have remained the backbone of treatment in patients with sarcoma. The introduction of immunotherapy has revolutionized the treatment of various solid and hematological malignancies. In this review, we discuss the basics of immunotherapy and the immune microenvironment in sarcomas; various modalities of immunotherapy, like immune checkpoint blockade, oncolytic viruses, cancer-targeted antibodies, vaccine therapy; and adoptive cell therapies like CAR T-cell therapy, T-cell therapy, and TCR therapy.

show abstract

1494P Regomune - a phase II study of regorafenib + avelumab in solid tumors: Results of the soft tissue sarcoma (STS) cohort

Cited by 2 publications

References 0 publications

Current Landscape of Immunotherapy for Advanced Sarcoma

Current Landscape of Immunotherapy for Advanced Sarcoma

Role of Immunotherapy in Sarcomas

Contact Info

Product

Resources

About